Urabe Akio
Division of Hematology, NTT Kanto Medical Center, Tokyo, Japan.
Gan To Kagaku Ryoho. 2005 Mar;32(3):287-91.
Myelodysplastic syndrome (MDS) is a heterogenous syndrome which has features of refractory anemia and preleukemic state due to the ineffective hematopoiesis of bone marrow cells. MDS is classified by the FAB classification and/or WHO classification, and has an International Prognostic Scoring System (IPSS) for evaluation of the prognosis. Available therapies consist of a variety of modalities from supportive therapy to hematopoietic stem cell transplantation, and are selected according to the condition of each patient.
骨髓增生异常综合征(MDS)是一种异质性综合征,由于骨髓细胞造血无效而具有难治性贫血和白血病前期状态的特征。MDS根据FAB分类和/或世界卫生组织(WHO)分类进行分类,并有一个国际预后评分系统(IPSS)用于评估预后。现有的治疗方法包括从支持治疗到造血干细胞移植的多种方式,并根据每个患者的情况进行选择。